Retatrutide LY-3437943 lyophilized peptide vial — OMNIPOTENT ≥99% HPLC research reference compound dosing protocols

LY-3437943 Dosing in Published Trial Protocols: A Research Reference for India Labs

One of the most common questions India research labs ask when sourcing Retatrutide as a reference compound is: what dose ranges appear in the published trial literature? This 2026 research-literature reference walks through the Phase 1 and Phase 2 trial dosing protocols for LY-3437943, explains how clinical-trial dosing relates to in-vitro concentration calculations, and provides reconstitution-volume math for India-based laboratory work.

This article is for research-literature context only. The dose figures referenced below are from published clinical trial protocols. They are not therapeutic recommendations and are not applicable to any individual outside of a registered clinical trial. Retatrutide is investigational and not approved by CDSCO or any other regulator.

TL;DR — dose ranges in published Retatrutide research

  • Phase 1 dose-escalation (single ascending dose): 0.1 – 8 mg subcutaneously, healthy adults.
  • Phase 1 multiple ascending dose: Titration from 0.5 mg up to 12 mg once weekly over multiple weeks.
  • Phase 2 obesity trial (Jastreboff et al., NEJM 2023): 1, 4, 8, 12 mg dose arms titrated to target over 4–12 weeks; 48-week treatment duration.
  • Phase 3 TRIUMPH programme: Doses include 4, 8, 12 mg in various indication trials.
  • In-vitro receptor-binding studies: Concentrations derived from published Kd/EC50 values, typically picomolar to low-nanomolar range for each of the three receptors.

The published Phase 1 literature

The first-in-human Phase 1 data on LY-3437943 was published by Coskun et al. (2022) in Cell Metabolism, with subsequent dose-escalation reports in 2023 and 2024. Key protocol features:

  • Single ascending dose (SAD): Healthy adults, single subcutaneous injection at 0.1, 0.3, 1, 3, 6, or 8 mg.
  • Multiple ascending dose (MAD): Healthy adults dosed once weekly for 12 weeks at multiple titration schedules ending at maximum doses up to 12 mg/week.
  • Pharmacokinetics: Half-life observed approximately 6 days, supporting once-weekly dosing. Maximum plasma concentration (Cmax) reached approximately 48 hours post-dose.
  • Receptor-engagement biomarkers: Published Phase 1 data observed dose-dependent changes in markers reflecting all three receptor pathways (GIP, GLP-1, glucagon).

The published Phase 2 trial in obesity (Jastreboff 2023)

The Phase 2 trial in obesity (clinicaltrials.gov NCT04881760) is the most-cited efficacy reference for LY-3437943. Protocol features:

  • Enrolled: 338 adults with obesity (BMI ≥30 kg/m², or 27–30 kg/m² with weight-related comorbidities).
  • Dosing arms: Placebo, 1 mg, 4 mg, 8 mg (with two titration schemes), 12 mg (with two titration schemes), all once weekly subcutaneously.
  • Titration: Started at 2 mg weekly, escalated over 4–12 weeks to target dose.
  • Duration: 48 weeks.
  • Primary endpoint: Percentage change in body weight from baseline at week 24.

Headline efficacy: 24.2% mean body-weight reduction at week 48 in the 12 mg arm. See our Retatrutide weight loss research summary for the full efficacy and safety data discussion.

Phase 3 (TRIUMPH programme) — ongoing trials in 2026

The Phase 3 TRIUMPH programme spans multiple parallel trials including:

  • TRIUMPH-1: Obesity in adults without type-2 diabetes — doses 4, 8, 12 mg.
  • TRIUMPH-2: Obesity in adults with type-2 diabetes.
  • TRIUMPH-3: Obesity in adults with metabolic-associated steatohepatitis (MASH).
  • TRIUMPH-4: Obesity in adults with cardiovascular disease.
  • Outcome trial: Long-term cardiovascular outcomes.

Most read-outs are expected in 2026–2027. Until then, Phase 2 remains the primary efficacy reference.

In-vitro concentrations vs in-vivo dose — the distinction matters

India laboratory researchers designing in-vitro studies should note that the milligram doses above are in-vivo subcutaneous administration doses for whole-organism studies. They are not directly comparable to in-vitro concentrations used in cell-culture or receptor-binding assays.

For in-vitro work, the relevant numbers are derived from the published receptor-binding parameters:

  • GLP-1R EC50 for Retatrutide: published in the picomolar to low-nanomolar range
  • GIPR EC50: similar range
  • Glucagon-R EC50: similar range but with class-specific potency differences

For receptor-engagement studies, researchers typically prepare stock solutions and dilute serially to cover a range from ~10⁻¹² M (picomolar) to ~10⁻⁶ M (micromolar) to construct a full dose-response curve.

Reconstitution math for India lab use

Practical calculation examples for a 10 mg lyophilised vial:

BAC water added Final concentration U-100 syringe equivalents
1 ml 10 mg/ml = 10,000 µg/ml 1 unit = 0.01 ml = 100 µg
2 ml 5 mg/ml = 5,000 µg/ml 1 unit = 50 µg
5 ml 2 mg/ml = 2,000 µg/ml 1 unit = 20 µg
10 ml 1 mg/ml = 1,000 µg/ml 1 unit = 10 µg

The 5 mg/ml reconstitution is the most common in published research-replication protocols because it makes the math simple: a 100 µg target = 2 syringe units; 1 mg target = 20 units; etc.

For in-vitro work at micromolar concentrations: from 5 mg/ml stock, dilute 1:1000 to get 5 µg/ml = ~1 µM (given Retatrutide MW ~4,731 Da). Further serial dilutions to construct dose-response curves.

Titration in the published trial protocols

Every published Retatrutide clinical-trial protocol uses titration — starting low and increasing over weeks — because rapid escalation produces unacceptably high rates of GI adverse events. The published titration patterns:

  • Phase 2 obesity trial: Start at 2 mg weekly, escalate every 4 weeks by 2 mg to target. Target arms reach 8 mg at week 16 and 12 mg at week 24.
  • Alternative "slower" arm: longer escalation over 12 weeks to test whether slower titration reduces GI AE rates.
  • Phase 1: Even slower escalation in some protocols to characterise the tolerability ceiling.

This matters for any researcher trying to interpret "dose" claims in popular media. "Retatrutide 12 mg" doesn't mean "start at 12 mg" — it means "reach 12 mg after a 16-week titration".

Half-life and dosing-frequency rationale

Retatrutide's ~6-day half-life supports once-weekly subcutaneous dosing. The fatty-acid modification on the peptide backbone binds serum albumin, slowing renal clearance and giving the long half-life. This is the same general strategy used by Semaglutide (~7 day half-life) and Tirzepatide (~5 day half-life).

For in-vitro studies, half-life is largely irrelevant — cell-culture experiments use fresh peptide at defined concentrations. For ex-vivo or animal-model studies, the published pharmacokinetics inform dosing-interval choice.

India sourcing for protocol design

For India research labs designing Retatrutide protocols, sourcing notes:

  • Lyophilised vial size: OMNIPOTENT offers 10 mg and 20 mg vials. The 10 mg vial is the most common for in-vitro work; the 20 mg vial is more economical per mg if multiple experiments are planned.
  • HPLC ≥99% per lot: Essential for any quantitative receptor-binding work. Lower-purity material introduces undefined impurities that confound binding-curve fits.
  • Batch COA on request: Email support with order number for the batch-specific Certificate of Analysis showing HPLC chromatogram, mass-spectrometry confirmation, and endotoxin testing.
  • BAC water bundling: 10 ml Bacteriostatic Water add-on at checkout is the standard reconstitution diluent.
  • Cold-chain handling: Pan-India dispatch in temperature-protected packaging — critical given Indian summer ambient temperatures.

India price — Retatrutide research-grade 2026

FAQ

What dose of Retatrutide is used in the most-cited weight-loss trial?
The Phase 2 trial (Jastreboff 2023) tested 1, 4, 8, and 12 mg/week dose arms with titration. Maximum efficacy was at 12 mg/week after 48 weeks.

How is in-vitro Retatrutide concentration calculated?
Use the published receptor-binding EC50 values (picomolar to nanomolar for each of GIPR, GLP-1R, glucagon-R) as the centre of your dose-response curve. Prepare a stock from the lyophilised powder, serial-dilute to cover ~10⁻¹² to 10⁻⁶ M.

Why is titration so slow in the published protocols?
To minimise GI adverse events (nausea, vomiting). Rapid escalation produces dose-limiting toxicity in the published Phase 1 literature.

Is the 12 mg dose definitive?
It's the highest dose tested in published Phase 2. Whether a higher dose (e.g., 15 mg) might produce additional efficacy is currently under investigation in the Phase 3 programme.

Where do India researchers buy lyophilised Retatrutide?
OMNIPOTENT dispatches from within India, HPLC ≥99%, batch COA on request.

Related research peptides and articles

Disclaimer: This article is provided for informational and research-literature context only. The dose figures referenced are from published clinical trial protocols. They are not therapeutic recommendations and are not applicable to any individual outside of a registered clinical trial. Retatrutide / LY-3437943 is investigational and not approved by CDSCO, FSSAI, the US FDA, or any other regulator for any human or veterinary use. Material sold is supplied strictly as a chemical reference standard for in-vitro laboratory research and analytical method development. By placing an order the purchaser affirms compliance with the Drugs and Cosmetics Act 1940, the Food Safety and Standards Act 2006, the Drugs and Magic Remedies (Objectionable Advertisements) Act 1954.

Back to blog